

First clinical study with CS1 completed

Cereno Scientific today announces that the company has completed its clinical study with drug candidate CS1. Preliminary analysis of the study data shows that CS1 was safe and well tolerated.

The study was performed in collaboration with Cereno Scientific's clinical research partner, CTC in Uppsala. In the study, individuals with an increased risk profile for thrombosis participated in evaluating safety, tolerability and pharmacokinetic properties of CS1. Furthermore, effects on risk markers for thrombosis were studied.

Cereno continues to analyse all data from the study and hopes to be able to present all results during the second quarter, including data on CS1 pharmacokinetics and potential pharmacodynamic effects.

“We are looking forward to the final results from the clinical study and, together with our secured financing up to 106 MSEK, this paves the way for our continued development work with the purpose to document CS1's efficacy for preventive thrombosis treatment in patients,” says Sten R. Sörensen.

Cereno Scientific is developing an improved treatment to protect against thrombosis-related disease, which is the leading cause of death worldwide. The company's drug candidate CS1 is being developed for the preventive treatment of patients at risk of thrombosis-related disease. The therapeutic potential of CS1 as a new therapy for preventive treatment of thrombosis has been confirmed in various preclinical studies. These studies in animals have shown that it is possible to reduce thrombosis formation by stimulating the body's own intelligent clot-busting mechanism, without an increased risk for bleeding side effects.

Related press releases

- [Cereno Scientific receives regulatory approval to start clinical study with its drug candidate CS1](#)
- [Cereno Scientific and CTC team up for a clinical study](#)
- [Positive data published in Journal of Thrombosis and Haemostasis \(JTH\)](#)
- [Cereno Scientific enters into a financing agreement with European High Growth Opportunities Securitization Fund through its advisor Alpha Blue Ocean](#)

For more information, please contact:

Sten R. Sörensen – VD

Tel: +46 73 374 03 74

E-mail sten.sorensen@cerenoscientific.com

www.cerenoscientific.com

Cereno Scientific AB

Visiting address AstraZeneca BioVentureHub Pepparedsleden 1, 431 50 Mölndal, Sweden
Postal address: Cereno Scientific AB, Erik Dahlbergsgatan 11A, SE-411 26 Göteborg, Sweden

Tel: +46 733 74 03 74, www.cerenoscientific.se

About Cereno Scientific AB

Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body's own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing thrombosis and treatment-related side effects – leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca's BioVentureHub and is supported by GU Ventures. Cereno Scientific's B share has been listed on AktieTorget since June 2016 with the ticker CRNO B, ISIN SE0008241558.

This information is such that Cereno Scientific AB is required to make public in accordance with the EU's market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made available publically by the Company's contact person on 18 April 2018.